Abstract
Background: Lucinactant (Surfaxin®) is the first available synthetic surfactant containing a peptide (sinapultide; KL4) that mimics human SP-B. There are currently no published pharmacoeconomic analyses comparing lucinactant to the animal-derived surfactants in the prevention of respiratory distress syndrome (RDS) in very low birth weight (VLBW) pre-term infants.
Objectives: To estimate the clinical consequences and economic impact of lucinactant and pooled animal-derived surfactants (beractant [Survanta®] and poractant alfa [Curosurf®]) in the prevention of RDS among surviving pre-term infants weighing 600 to 1,250 grams.
Methods: A decision-analytic model was constructed using a hospital perspective to assess the pharmacoeconomics of surfactant replacement therapy. Data sources: a) epidemiologic data regarding low birth weight and VLBW infants is from the U.S. National Centers for Health Statistics (2003), and the Vermont Oxford Network (2004); b) clinical outcomes are from two randomized, controlled clinical trials of surfactant therapy (SELECT and STAR); and c) cost data is from an assessment of daily neonatal intensive care unit (NICU) costs for 244 pre-term infants with severe RDS (2004). Cost variables: Average cost of a day in the NICU on mechanical ventilation (MV) was U.S. $2,386 and was U.S. $1,565 off MV; surfactant pharmacy costs were included at price parity from the Red Book (2005).
Results: Surviving infants who received lucinactant compared to pooled animal-derived surfactants had 4.14 fewer NICU days (mean 75.68 days vs. 79.82 days, respectively). Fewer NICU days convert into a total cost savings per infant who survived of U.S. $5,841 in the lucinactant group compared to the pooled animal-derived cohort. Conclusions: When compared to pooled animal-derived surfactants, the synthetic surfactant lucinactant may reduce total initial NICU hospital costs in surviving infants who receive surfactant therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gdovin, J., Moya, F., Gadzinowski, J. et al. 140 Preventing Respiratory Distress Syndrome: A Comparative Pharmacoeconomic Analysis of Lucinactant (Surfaxin) Versus Pooled Animal-Derived Surfactants. Pediatr Res 58, 378 (2005). https://doi.org/10.1203/00006450-200508000-00169
Issue Date:
DOI: https://doi.org/10.1203/00006450-200508000-00169